.png)
Addex Therapeutics (NASDAQ:ADXN) has led a CHF 2 million investment in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders.
The funding will enable Stalicla to advance its autism-focused drug candidates, support asset partnering, prepare for its Series C financing, and
English (US) ·